AU2003290673B2 - Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors - Google Patents

Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors Download PDF

Info

Publication number
AU2003290673B2
AU2003290673B2 AU2003290673A AU2003290673A AU2003290673B2 AU 2003290673 B2 AU2003290673 B2 AU 2003290673B2 AU 2003290673 A AU2003290673 A AU 2003290673A AU 2003290673 A AU2003290673 A AU 2003290673A AU 2003290673 B2 AU2003290673 B2 AU 2003290673B2
Authority
AU
Australia
Prior art keywords
optionally substituted
group
groups
atoms
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003290673A
Other languages
English (en)
Other versions
AU2003290673A1 (en
Inventor
Zheng Hoi Cheng
Alan Davison
Alun G. Jones
Ashfaq Mahmood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Harvard University
Original Assignee
Massachusetts Institute of Technology
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology, Harvard University filed Critical Massachusetts Institute of Technology
Publication of AU2003290673A1 publication Critical patent/AU2003290673A1/en
Application granted granted Critical
Publication of AU2003290673B2 publication Critical patent/AU2003290673B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40Y being a hydrogen or a carbon atom
    • C07C323/41Y being a hydrogen or an acyclic carbon atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/24Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/25Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005Compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003290673A 2002-11-08 2003-11-08 Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors Ceased AU2003290673B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42498002P 2002-11-08 2002-11-08
US60/424,980 2002-11-08
PCT/US2003/035618 WO2004043380A2 (en) 2002-11-08 2003-11-08 Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors

Publications (2)

Publication Number Publication Date
AU2003290673A1 AU2003290673A1 (en) 2004-06-03
AU2003290673B2 true AU2003290673B2 (en) 2011-01-06

Family

ID=32312909

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003290673A Ceased AU2003290673B2 (en) 2002-11-08 2003-11-08 Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors

Country Status (6)

Country Link
US (1) US20060159617A1 (enExample)
EP (1) EP1567495A4 (enExample)
JP (1) JP4796301B2 (enExample)
AU (1) AU2003290673B2 (enExample)
CA (1) CA2505529C (enExample)
WO (1) WO2004043380A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
JP4705695B2 (ja) 2007-10-11 2011-06-22 アストラゼネカ アクチボラグ プロテインキナーゼb阻害剤としてのピロロ[2,3−d]ピリミジン誘導体
WO2010144891A1 (en) * 2009-06-13 2010-12-16 President And Fellows Of Harvard College Compositions and methods for imaging tissues, organs and tumors
JP5894540B2 (ja) 2010-02-18 2016-03-30 ブイティーブイ・セラピューティクス・エルエルシー フェニル−ヘテロアリール誘導体とその使用の方法
JP6080837B2 (ja) 2011-04-01 2017-02-15 アストラゼネカ アクチボラグ 療法的治療
CN102219818B (zh) * 2011-05-05 2014-01-08 江苏省原子医学研究所 胸苷衍生物及其制备方法和其作为配体在制备肿瘤显像剂中的应用
KR102035361B1 (ko) 2011-11-30 2019-11-08 아스트라제네카 아베 암의 병용 치료
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2015200187A1 (en) * 2014-06-27 2015-12-30 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037055A1 (en) * 1997-02-19 1998-08-27 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4638051A (en) * 1984-04-30 1987-01-20 The Johns Hopkins University Brain imaging radiopharmaceuticals
ZA852981B (en) * 1984-04-30 1985-11-27 Univ Johns Hopkins Brain imaging radiopharmaceuticals
US6241963B1 (en) * 1995-10-19 2001-06-05 The Trustees Of The University Of Pennsylvania Dopamine and serotonin transporter ligands and imaging agents
US6171576B1 (en) * 1995-11-03 2001-01-09 Organix Inc. Dopamine transporter imaging agent
CA2285516C (en) * 1999-05-12 2010-12-07 President And Fellows Of Harvard College Dopamine transporter imaging agents
US6515131B2 (en) * 2000-02-22 2003-02-04 Biostream Therapeutics, Inc. Imagining agents for diagnosis of Parkinson's disease
AU6968301A (en) * 2000-04-28 2001-11-12 Harvard College Small technetium-99m and rhenium labeled agents and methods for imaging tumors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037055A1 (en) * 1997-02-19 1998-08-27 The George Washington University Compounds, compositions, and methods for cancer imaging and therapy

Also Published As

Publication number Publication date
JP4796301B2 (ja) 2011-10-19
EP1567495A4 (en) 2007-10-31
US20060159617A1 (en) 2006-07-20
AU2003290673A1 (en) 2004-06-03
CA2505529A1 (en) 2004-05-27
WO2004043380A2 (en) 2004-05-27
JP2006505616A (ja) 2006-02-16
WO2004043380A8 (en) 2005-06-23
WO2004043380A3 (en) 2004-12-29
CA2505529C (en) 2013-12-24
EP1567495A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
US10039845B2 (en) Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents
US20080226550A1 (en) Small technetium-99m and rhenium labeled agents and methods for imaging tumors
AU2003290673B2 (en) Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
Friebe et al. [99mTc] oxotechnetium (V) complexes of amine-amide-dithiol chelates with dialkylaminoalkyl substituents as potential diagnostic probes for malignant melanoma
AU2001269683A1 (en) Small technetium-99m and rhenium labeled agents and methods for imaging tumors
AU2015203742B2 (en) Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
US8747810B2 (en) Compositions and methods for imaging tissues, organs and tumors
Ogawa et al. Syntheses and evaluation of a homologous series of aza-vesamicol as improved radioiodine-labeled probes for sigma-1 receptor imaging
Kraemer et al. Matthias Friebe, Ashfaq Mahmood,*, Cristina Bolzati, Antje Drews, Bernd Johannsen, Michael Eisenhut,||
HK1215249B (en) Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired